Actively Recruiting
Study to Evaluate How BI 1291583 is Absorbed in Adults With and Without Liver Problems Using a Single Oral Dose
Led by Boehringer Ingelheim · Updated on 2026-10-13
32
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how a medicine called BI 1291583 is absorbed into the blood of adults aged 18 to 80 years, including those with and without liver problems. The study focuses on people with bronchiectasis, a chronic lung disease often accompanied by liver issues. Understanding how liver problems affect the medicines blood levels can help guide future treatments. Participants receive a single oral dose of BI 1291583. They are divided into four groups based on liver function healthy, mild, moderate, or severe liver impairment. Each healthy participant is matched with participants in the other groups by age, sex, smoking habits, and body weight to ensure fair comparisons. Liver impairment is classified using the Child-Pugh score, which assesses liver disease severity. The study lasts about three months with participants staying three days at the study site and attending up to nine visits. During these visits, doctors collect health information and take regular blood samples to measure the medicines levels over time. They also monitor participants for any side effects to evaluate safety and tolerability.
CONDITIONS
Brief Title
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
Research Team
B
Boehringer Ingelheim
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here